Trial Profile
TCR peptide vaccination in MS induces high levels of IL-10 and restores decreased FOXP3 levels.
Status:
Not stated
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs IR 902 (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 05 Nov 2010 New trial record.